BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Former Roche (RHHBY) Head Of CNS R&D Joins Gastrotech Pharma A/S Board Of Directors


10/19/2005 5:11:51 PM

COPENHAGEN, Denmark, October 18 /PRNewswire/ -- Tamas Bartfai, Ph.D., is the director of the Harold L. Dorris Neurological Research Center at The Scripps Research Institute, La Jolla, CA. In addition, he holds the Harold L. Dorris Chair in Neuroscience. Professor Bartfai is former head of central nervous system research at Hoffman-La Roche where he served as Senior Vice President. Previously, he was at Stockholm University, as Chairman, Department of Neurochemistry and Neurotoxicity. Born in Budapest, Hungary, he received his undergraduate education there at Eotvos Lorand University and a Ph.D. in biochemistry at Stockholm. Dr. Bartfai is a Board Member of a number of US Biotech firms and advises a number of large investment banks on Pharma/Biotech.

"We are delighted and honored to welcome Tamas Bartfai to our Board of Directors", says Claes Post, CEO of Gastrotech. "Professor Bartfai brings tremendous experience and knowledge to our Board. This will be a great help in our on-going process of bringing our clinical stage programs forward towards proof of concept".

Professor Olle Isaksson, Chairman of the Board of Directors of Gastrotech Pharma A/S adds: "Professor Bartfai is known for his extensive insight into many of the key aspects of drug development. He will strengthen our board tremendously and provide us with excellent connections to his wide-spread network."

About Gastrotech Pharma A/S

Gastrotech Pharma A/S is a biopharmaceutical company focusing on medical applications of gastrointestinal hormones. The company is founded on the basis of research carried out at the medical faculty of Gothenburg University. The scientists are world leading experts in the field of endocrinology and have made ground breaking contributions to the field through pre-clinical and clinical studies. Professor John-Olov Jansson, Professor Olle Isaksson and co-workers are among the founders of the company. Gastrotech Pharma develops pharmaceutical products for clinical evaluation in several diseases of large unmet medical needs to significantly improve the patient's quality of life.

Gastrotech has two programs in clinical development: GLP-1 for Irritable Bowel Syndrome, and Ghrelin for the treatment of cachexia and other catabolic syndromes. More information is available at http://www.gastrotechpharma.com/.

Gastrotech A/S

CONTACT: For further information contact: Claes Post, CEO, GastrotechPharma A/S, at +45-33-44-42-42



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES